GLP-1 Medications and DUI Cases: Rethinking Alcohol Absorption and BAC Interpretation

I have been receiving an increasing number of forensic toxicology inquiries involving GLP-1 medications and alcohol-related DUI cases.

And they raise an interesting scientific question:

Can medications such as semaglutide or tirzepatide change the way we interpret alcohol concentrations?

The answer is more complicated than simply saying yes or no.

GLP-1–based medications have transformed the treatment of diabetes and obesity. One of their known pharmacological effects is an influence on gastric emptying.

Why might that matter in an alcohol case?

Alcohol pharmacokinetics depend, in part, on how quickly alcohol moves from the stomach into the small intestine, where absorption occurs rapidly.

If gastric emptying is altered, the timing of alcohol absorption and the shape of the blood alcohol concentration curve may potentially be altered as well.

That raises important forensic questions when attempting to reconstruct a person’s BAC at an earlier time:

Was the individual still absorbing alcohol at the time of driving?

Could peak BAC have occurred later than ordinarily expected?

How much time elapsed between drinking, driving, and blood or breath testing?

When was the last meal and the last drink?

Which GLP-1 medication was being taken, at what dose, and where was the individual in the dosing schedule?

Is retrograde extrapolation scientifically appropriate given the available information?

These questions matter because traditional alcohol calculations often rely on assumptions about when absorption was complete.

If that assumption is uncertain, calculating backward from a later BAC to estimate an earlier BAC may carry additional uncertainty.

But an equally important point is this:

Taking a GLP-1 medication does NOT automatically invalidate a breath or blood alcohol result.

Nor does delayed gastric emptying automatically establish that someone’s BAC was lower at the time of driving.

The scientific question is more specific:

Does the individual’s medication history, drinking pattern, food intake, timeline, toxicology results, and available pharmacological evidence support a different interpretation of the alcohol concentration in that particular case?

Emerging human research has begun examining GLP-1 medications and alcohol pharmacokinetics, including evidence suggesting a delayed rise in breath alcohol under some conditions. But this remains a developing area of science, and broad conclusions should be approached cautiously.

That is why these cases require case-specific pharmacological and forensic toxicological evaluation rather than assumption.

As GLP-1 medication use continues to expand, questions surrounding alcohol absorption, BAC interpretation, and retrograde extrapolation may become increasingly important in DUI litigation.

Based on the inquiries I am receiving, that conversation has already begun.